TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 80 years of age~* Good physical health based upon medical history and physical examination~* Willing and able to participate in the entire study duration~* Female subject with a negative urine pregnancy test immediately prior to study vaccination~Exclusion Criteria:~* Chronic skin infections or a chronic skin condition (e.g. psoriasis)~* Serious S. aureus infection in the last 12 months~* Allergy to aluminum-containing substance taken in the body or to any other vaccine component~* Oral temperature equal to or greater than 100.4ºF (38.0ºC), within the past 2 days~* Participation in a prior V710 vaccine clinical study~* Participation in any other clinical study in the past 4 weeks, or during the 3-month study duration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): V710
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 18 and 65 years of age, inclusive, who were diagnosed with migraines at ≤ 50 years of age, and have a history of chronic migraine for ≥ 12 months before screening.~Exclusion Criteria:~* Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening.~* Confounding and clinically significant pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome).~* Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to screening. Patients with a lifetime history of psychosis, mania, or dementia are excluded.~* History or diagnosis of complicated migraine (ICHD-III beta version, 20134), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or sporadic and familial hemiplegic migraine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ALD403 (Eptinezumab) Dose Level 1 (Type: EXPERIMENTAL): ALD403 (Eptinezumab) Dose Level 1 (IV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas not amenable to standard curative therapy Duct cell Undifferentiated The following cellular types are not eligible: Islet cell carcinoma Acinar cell carcinoma Cystadenocarcinoma No CNS metastases~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 No underlying disease associated with active bleeding Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN AST no greater than 3 times ULN PT and PTT normal Renal: Creatinine no greater than 1.5 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 6 months after study~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy or immunotherapy No concurrent immunotherapy No colony-stimulating factors during first course of therapy Chemotherapy: No prior chemotherapy except radiosensitizing agents used in adjuvant setting or in treatment of locally advanced disease No prior gemcitabine No prior ISIS 2503 No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to 25% or greater of bone marrow No concurrent radiotherapy Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine + ISIS 2503 (Type: EXPERIMENTAL): Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and ISIS 2503 IV continuously on days 1-14. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of malignant solid cancer, ECOG 0-2.~* Disease progression on established treatments or patients not eligible to standard options.~* Signed informed consent must be obtained.~Exclusion Criteria:~* Pregnancy.~* Life expectancy less than 3 months.~* Any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures.~* Patients with severe systemic autoimmune disease.~* Patients that do not consent to that tissue and blood samples are stored in a biobank.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AdCD40L (Type: EXPERIMENTAL): Treatments once a week with 2.5x10e11 VP AdCD40L, maximum 4 treatments (total dose 1x10e12 VP). If no effect in less than 2 out of 6 melanoma patients, the following 9 melanoma patients and 6 patients with other solid tumors will receive preconditioning therapy 1-2 days prior to first and last treatment with 300mg/m2 cyclophosphamid. The next 9 melanoma patients will receive one local radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted at the Gynecological emergency Unit at Hospital de Clínicas de Porto Alegre scheduled for uterine evacuation with \<12 weeks of gestation.~Exclusion Criteria:~* patients who do not wish to participate in the project;~* patients with ectopic pregnancy;~* patients with comorbidities (heart failure congestive, chronic obstructive pulmonary disease);~* patients with hypovolemic shock;~* patients with cervical incompetence;~* patients with infected miscarriage/abortion (presence of fever, pus from the cervix, leukocytosis \[\> 14000\]);~* patients with twin pregnancy;~* patients with Marfan syndrome;~* patients allergic to misoprostol;~* patients with coagulopathy;~* patients with opening of cervical internal os (4 mm of dilatation at the time of consultation);~* patients with previous surgery of the cervix (conization);~* patients with concomitant use of IUDs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Misoprostol 400 µg (Type: ACTIVE_COMPARATOR): Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.
- Misoprostol 200 µg (Type: EXPERIMENTAL): Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study Between the Roles of Intrauterine Misoprostol Versus the Sublingual Route for Prevention of Postpartum Blood Loss in Elective Cesarean Sections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 20-35 years.~2. BMI \< 30kg/m2.~3. Singleton pregnancy.~4. Full term pregnancies (recruiting from 37 weeks of gestation).~5. Elective cesarean section (previous one or two cesarean section).~Exclusion Criteria:~1. Active labour before 39 weeks.~2. Uterine over distension as due to multiple pregnancies or polyhydramnios.~3. Multipara \[parity ≥3\].~4. Pregnancy with obstetric haemorrhage such as placenta Previa, placental abruption or vasa Previa.~5. Moderate to severe anemia with HB \<9mg/dL.~6. Pregnancy with coagulopathy, thrombocytopenia or blood dyscrasias.~7. Women with uterine fibroids.~8. Medically complicated pregnancy (pregnancy induced hypertension, cardiovascular, DM, hepatic, or renal disorders).~9. Women with any contraindication for the use of misoprostol or oxytocin as a history of prostaglandin allergy and current medication which could cause severe drug interaction to prostaglandins such as topical dinoprostone, magnesium-containing antacids or quinapril.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- intrauterine misoprostol group (Group A) (Type: EXPERIMENTAL): 96 women receiving 400 mcg intrauterine misoprostol + IV oxytocin.
- sublingual misoprostol group (Group B) (Type: ACTIVE_COMPARATOR): : 96 women receiving 400 mcg sublingual misoprostol + IV oxytocin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:- Fitzpatrick Skin type I or II~* Nonpregnant Females, age 18-30 or 50-70~* Body Mass Index Normal or Overweight~* If age 18-30, must be non-smoker~* Willing to fast for 8 hours prior to a blood draw; Exclusion Criteria:- History of cosmetic surgery~* Use of anti-aging medications within 3 months of enrollment~* Use of over-the-counter anti-aging creams (not sunscreens) more than once per week within one month of enrollment~* Use of dietary supplements including vitamins within one month of enrollment~* Use of tanning beds or excessive UV exposure (greater than 2 hours per day) within one month of enrollment~* Use of sunless tanners within one month of enrollment~* Uncontrolled or ongoing serious medical condition~* Participation in another clinical study involving use of an investigational drug or product~* Medical condition which, at the discretion of the investigator, will have a significant impact on ability to judge participant's skin characteristics, including age.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Nonsmoker (Type: OTHER): Nonsmokers Intervention: Dietary Supplement: LifePak Nano
- Smoker (Type: OTHER): Smoker arm Intervention: Dietary Supplement: LifePak Nano

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Histologically or cytologically confirmed pancreas adenocarcinoma receiving initial chemotherapy for metastatic disease and without evidence of disease progression on treatment~* Patients with measurable disease and/or non-measurable or no evidence of disease assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in this study.~* Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or suspected deleterious~* Patients are on treatment with a first line platinum-based (cisplatin, carboplatin or oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16 weeks of continuous platinum treatment and have no evidence of progression based on investigator's opinion.~* Patients who have received platinum as potentially curative treatment for a prior cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for pancreas cancer are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and initiation of the platinum-based chemotherapy for metastatic pancreas cancer.~Major Exclusion Criteria:~* gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg, Variants of uncertain clinical significance or Variant of unknown significance or Variant, favour polymorphism or benign polymorphism etc.)~* Progression of tumour between start of first line platinum based chemotherapy for metastatic pancreas cancer and randomisation.~* Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle~  1 Day 1 is not permitted.~* Exposure to an investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisation~* Any previous treatment with a PARP inhibitor, including Olaparib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Olaparib (Type: EXPERIMENTAL): Olaparib tablets po. 300 mg twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~* Patients with a diagnosis of Fanconi's anemia AND Aplastic anemia OR Myelodysplastic syndrome OR Acute leukemia with or without chromosomal anomalies Aplastic anemia as defined by having at least one of the following: Platelet count less than 20,000/mm3 Absolute neutrophil count less than 500/mm3 Hemoglobin less than 8 g/dL~* Myelodysplastic syndrome with multilineage dysplasia With or without chromosomal anomalies~* Hematologic malignancy (e.g., acute myeloid leukemia, acute lymphoblastic leukemia, or B-cell non-Hodgkin's lymphoma)~* No greater than 30% blasts in bone marrow or greater than 5% blasts in peripheral blood~* No active CNS leukemia at time of transplantation~* Must have an HLA A, B, DRB1 identical or 1 antigen mismatched related (nonsibling) or unrelated bone marrow, peripheral blood, or umbilical cord blood donor~--Prior/Concurrent Therapy--~* Radiotherapy: No prior radiotherapy that would preclude total body irradiation~* Surgery: Not specified~--Patient Characteristics--~* Performance status: Karnofsky 70-100% OR Lansky 50-100%~* Hematopoietic: See Disease Characteristics~* Hepatic: No hepatic failure (e.g., coagulopathy or ascites)~* Renal: Creatinine clearance at least 40 mL/min~* Cardiovascular: Ejection fraction at least 45%~* Other: No active uncontrolled infection within one week of transplantation No malignant solid tumor (e.g., squamous cell carcinoma of the head, neck, or cervix) within 2 years of transplantation Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 34 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum, metastatic disease~* Wild-type KRAS tumor status~* Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2~* Must have failed a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease~* Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of colorectal cancer (CRC)~* Adequate hematologic, renal, hepatic and metabolic function~Exclusion Criteria:~* Symptomatic brain metastases requiring treatment~* Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, panitumumab or cetuximab) or treatment with small molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib)~* Antitumor therapy (eg, chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy ≤ 30 days before randomization.~* Clinically significant cardiovascular disease~* Active infection requiring systemic treatment or any uncontrolled infection ≤14 days prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab (Type: ACTIVE_COMPARATOR): Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.~Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
- Panitumumab (Type: EXPERIMENTAL): Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient (male or female) requiring emergency endotracheal intubation.~Exclusion Criteria:~* Children (\<18 years old).~* Women who are known to be pregnant.~* Any patient who has been previously randomized in the EvK Trial.~* Patients who require endotracheal intubation without sedative medication. For example, patients in full cardiac arrest.~* Patients with a known allergy to ketamine or etomidate.~* Any individual wearing a MedAlert bracelet indicating that he/she has formally opted out of the EvK Trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etomidate (Type: EXPERIMENTAL): Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
- Ketamine (Type: EXPERIMENTAL): Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to give written informed consent and comply with the requirements of the study protocol~* Negative serum pregnancy test (for women of child bearing age)~* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of treatment.~* IgG \& IgM levels within normal limits~* Adequate renal function as indicated by serum creatinine measurements.~* No previous biological use (investigational or approved) except for the three approved anti-TNF alpha therapies~* Patients who have been treated with anti-TNF alpha therapies must be off of infliximab and adalimumab for two months before study entry and off of etanercept for one month before study entry~* No use of phosphodiesterase type 5 inhibitors (PDE5) (i.e. Sildenafil, Tadalafil, and Vardenafil) 1 week prior to the study and during the course of the study.~* SBP ≤ 140/90 for two months prior to study enrollment~Exclusion Criteria:~* Prior history of MI, CVA, CABG, PTCA, or peripheral vascular disease~* Any serious concomitant medical condition that could interfere with the study.~* Patients with insulin dependent diabetes~* Failure to provide written consent.~* Individuals with HIV infections~* SBP \> 140/90 at two months prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituxan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete